Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 61fludarabine phosphate 52Peripheral Blood Stem Cell Transplantation 41Busulfan 41Tacrolimus 36Antilymphocyte Serum 34Mycophenolic Acid 33Radiotherapy 30Melphalan 27Filgrastim 27Cyclosporine 25Methotrexate 23Whole-Body Irradiation 21fludarabine 20Methylprednisolone 18Etoposide 17Cord Blood Stem Cell Transplantation 15sargramostim 10Cytarabine 10Rituximab 9Alemtuzumab 9Sirolimus 8Granulocyte Colony-Stimulating Factor 8Epoetin Alfa 7Carmustine 7Stem Cell Transplantation 6Psychiatric Rehabilitation 6Prednisone 6Flow Cytometry 6Trimethoprim, Sulfamethoxazole Drug Combination 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × Glycopeptides × Other hematologic neoplasm × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡